Related Experiment Video
Updated: Jul 30, 2025
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
Published on: April 16, 2019
Multiple therapeutic approaches of glioblastoma multiforme: From terminal to therapy
Smita Kumari1, Rohan Gupta1, Rashmi K Ambasta1
1Molecular Neuroscience and Functional Genomics Laboratory, Department of Biotechnology, Delhi Technological University, India.
Abstract:
Glioblastoma multiforme (GBM) is an aggressive brain cancer showing poor prognosis. Currently, treatment methods of GBM are limited with adverse outcomes and low survival rate. Thus, advancements in the treatment of GBM are of utmost importance, which can be achieved in recent decades. However, despite aggressive initial treatment, most patients develop recurrent diseases, and the overall survival rate of patients is impossible to achieve. Currently, researchers across the globe target signaling events along with tumor microenvironment (TME) through different drug molecules to inhibit the progression of GBM, but clinically they failed to demonstrate much success. Herein, we discuss the therapeutic targets and signaling cascades along with the role of the organoids model in GBM research. Moreover, we systematically review the traditional and emerging therapeutic strategies in GBM. In addition, we discuss the implications of nanotechnologies, AI, and combinatorial approach to enhance GBM therapeutics.
Insights
Glioblastoma multiforme (GBM) treatments face challenges due to aggressive recurrence. This review explores novel therapeutic targets, signaling pathways, and advanced models like organoids to improve GBM treatment strategies.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Translational Medicine
Background:
- Glioblastoma multiforme (GBM) is an aggressive brain cancer with poor prognosis and limited treatment options.
- Despite initial treatments, GBM frequently recurs, leading to low patient survival rates.
- Current therapeutic strategies targeting signaling events and the tumor microenvironment (TME) have shown limited clinical success.
Approach:
- Systematic review of traditional and emerging therapeutic strategies for GBM.
- Discussion of therapeutic targets and signaling cascades implicated in GBM progression.
- Exploration of the role of organoid models in advancing GBM research.
Key Points:
- Organoid models offer a promising platform for studying GBM biology and testing therapeutics.
- Nanotechnology, artificial intelligence (AI), and combinatorial approaches show potential to enhance GBM treatment efficacy.
- Understanding signaling pathways and the TME is crucial for developing effective GBM therapies.
Conclusions:
- Advancements in understanding GBM pathogenesis are critical for improving patient outcomes.
- Emerging technologies and novel therapeutic strategies are essential to overcome treatment resistance in GBM.
- A multi-faceted approach integrating new models and technologies is needed to enhance GBM therapeutics.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...